1308 related articles for article (PubMed ID: 23527621)
1. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
2. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
4. Epoetin biosimilars in Europe: five years on.
Mikhail A; Farouk M
Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
6. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
7. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
9. Developing clinical trials for biosimilars.
Bui LA; Taylor C
Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
[TBL] [Abstract][Full Text] [Related]
10. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view.
Pineda C; Caballero-Uribe CV; de Oliveira MG; Lipszyc PS; Lopez JJ; Mataos Moreira MM; Azevedo VF
Clin Rheumatol; 2015 Apr; 34(4):635-40. PubMed ID: 25673060
[TBL] [Abstract][Full Text] [Related]
11. Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists.
Griffith N; McBride A; Stevenson JG; Green L
Hosp Pharm; 2014 Oct; 49(9):813-25. PubMed ID: 25477613
[TBL] [Abstract][Full Text] [Related]
12. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
Felix T; Jordan JB; Akers C; Patel B; Drago D
Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar medical products - licensing, pharmacovigilance and interchangeability.
Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414
[TBL] [Abstract][Full Text] [Related]
14. Comparability and biosimilarity: considerations for the healthcare provider.
Lee JF; Litten JB; Grampp G
Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars and the European experience: implications for the United States.
Megerlin F; Lopert R; Taymor K; Trouvin JH
Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
[TBL] [Abstract][Full Text] [Related]
16. Similar names for similar biologics.
Casadevall N; Felix T; Strober BE; Warnock DG
BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
[TBL] [Abstract][Full Text] [Related]
17. Biologicals and biosimilars: safety issues in Europe.
Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A
Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: A Multidisciplinary Perspective.
Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
[TBL] [Abstract][Full Text] [Related]
20. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
